This Week in Endocrinology — Sep 9, 2026

Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning diabetes complications and how we might actually modify them, the messy practicalities of cortisol testing and adrenal surgery, and the shifting landscape of rare endocrine disease and obesity medicine. Let's dive in.

We'll start with diabetes complications, because three papers this week ask the same underlying question from different angles: can we do more than watch these complications progress? In the Journal of Clinical Endocrinology and Metabolism, Tan and colleagues report a target trial emulation using United Kingdom primary care data, comparing just over sixteen thousand new users of fenofibrate with around twenty-six thousand matched statin users, all with type 2 diabetes, followed for up to twelve years [1]. Fenofibrate was associated with about a thirteen percent lower risk of sight-threatening retinopathy in the intention-to-treat analysis, and roughly a twenty percent reduction among those who actually stayed on treatment. The effect held across age, sex and baseline lipid levels, with one notable exception: no protective association was seen in patients of South Asian origin, which is a signal worth remembering given how much of the type 2 diabetes burden sits in that population. This is observational, so confounding by indication cannot be fully excluded, but it aligns the real-world data with the earlier randomised evidence and strengthens the case for thinking of fenofibrate as retinopathy-directed therapy rather than purely a triglyceride drug.

Staying with complications, Diabetes Care published the PDN-Sensory randomised trial from Hurley and colleagues, testing high-frequency ten-kilohertz spinal cord stimulation added to conventional medical management in ninety-one patients with painful diabetic neuropathy [2]. The pain results were emphatic — among those who proceeded to a temporary stimulation trial, twenty-seven of thirty-four achieved at least fifty percent pain relief, versus just two of fifty patients on medical management alone. What makes this trial more interesting than a pain study is the blinded, objective sensory data: sensory improvement on the modified Toronto Clinical Neuropathy Score occurred in about fifty-five percent of stimulated patients versus a quarter of controls, and intraepidermal nerve fibre density in the lower calf actually increased slightly with stimulation while it drifted down with usual care. Eight of ten hierarchical secondary endpoints, including sleep and quality of life, were met. The authors are appropriately cautious in calling this only consistent with a possible disease-modifying effect at six months — but for the patient with refractory neuropathic pain in whom you have exhausted the usual agents, this is a referral worth considering.

The third paper in this group is a perspective rather than a trial. Also in Diabetes Care, Rosen and colleagues, writing across endocrinology, nephrology and cardiology, lay out a roadmap for finally getting sodium-glucose cotransporter inhibitors properly tested for cardiac and kidney protection in type 1 diabetes [3]. Their argument is that the mechanisms driving benefit in type 2 diabetes and in non-diabetic kidney and heart disease are very likely to apply in type 1, and that registrational trials could therefore rely on surrogate endpoints rather than being powered for hard events, which would make them feasible. The counterweight, of course, is diabetic ketoacidosis, and they are blunt that mitigation protocols exist but rigorous evidence that they work is lacking. The practical message for now is that off-label use in type 1 diabetes remains a decision that carries real ketoacidosis risk and demands structured patient education.

Our second theme is cortisol — specifically, how easily our diagnostic tests and post-operative management can mislead us. In the Journal of Clinical Endocrinology and Metabolism, Tizianel and colleagues measured serum dexamethasone alongside cortisol in 546 patients undergoing the one-milligram overnight dexamethasone suppression test [4]. Median dexamethasone concentration was around twelve nanomoles per litre, and both older age and higher body mass index were independently associated with higher dexamethasone exposure, while kidney function was not. Concomitant proton pump inhibitors, statins and calcium channel blockers looked influential in simple analyses but largely fell away after adjustment. Suboptimal dexamethasone exposure was uncommon, occurring in a little over three percent of patients, but when it happened it was frequently accompanied by inadequate cortisol suppression — in other words, a false positive. The pragmatic takeaway is that measuring dexamethasone is most useful in the patient who fails to suppress, to distinguish true non-suppression from poor drug exposure; above the adequate threshold, more dexamethasone buys you nothing.

That interpretive caution matters most in the group covered by Liu, Yi and Tan in the same journal, an approach-to-the-patient review on Cushing's syndrome in older adults [5]. Their central point is that the tests are the same but the thresholds for suspicion, the interpretation, and the therapeutic goal all differ. Older patients often lack the classic cushingoid phenotype and instead present with abruptly deteriorating diabetes or hypertension, recurrent falls, rapid bone loss, venous thromboembolism, cognitive decline, or an adrenal incidentaloma — features that overlap heavily with ordinary ageing, creating symmetrical risks of missing real disease and over-treating trivial biochemistry. Late-night salivary cortisol needs repeating and cautious reading in patients with diabetes or disturbed sleep; urinary free cortisol can be falsely low in chronic kidney disease. And their management advice is functional status, not chronological age: offer fit older patients standard curative surgery, and consider staged or symptom-directed approaches in the frail.

Once you have operated, how long does the axis take to recover? A multicentre cohort in the European Journal of Endocrinology from Lee and colleagues followed 139 adults with mild autonomous cortisol secretion and 280 with overt adrenal Cushing syndrome after unilateral adrenalectomy, all of whom needed glucocorticoid replacement [6]. Median time to stopping glucocorticoids was about eight months in mild autonomous cortisol secretion and close to fifteen months in adrenal Cushing syndrome. Older age consistently predicted slower recovery in both groups, as did higher post-dexamethasone cortisol, while a higher baseline ACTH predicted faster recovery. That gives you concrete numbers for the counselling conversation — and a reminder not to promise a mild-cortisol patient that they will be off hydrocortisone in a couple of months.

Our third theme is rare and lifelong endocrine disease. The Lancet Diabetes and Endocrinology published a review from Brandi and colleagues on chronic hypoparathyroidism, tracking a genuine shift from calcium and active vitamin D toward restoring physiology [7]. Long-acting parathyroid hormone analogues — palopegteriparatide, eneboparatide, canvuparatide — provide sustained receptor activation with reduced need for calcium and activated vitamin D, while calcilytics such as encaleret target calcium-sensing receptor overactivity in autosomal dominant hypocalcaemia type 1, with possible broader application. Alongside these, they cover parathyroid transplantation, graft preservation, and stem-cell based regenerative work, plus emerging diagnostics including targeted genetic testing and point-of-care calcium monitoring. Complementing that, a Swiss population-based study in the Journal of Clinical Endocrinology and Metabolism examined over twelve and a half million hospitalisations and identified around two thousand involving congenital adrenal hyperplasia [8]. Endocrine and metabolic disorders were the leading admission reason at every age, most dramatically in infancy. Comorbidity burden was striking: patients with congenital adrenal hyperplasia carried an average of five and a half diagnoses per hospitalisation at birth, a burden the comparison population only reached around age sixty. Intensive care admission risk was about fifty percent higher overall, with the widest gap in neonates and infants. Both papers point the same direction — rare endocrine disease is a lifelong, high-acuity condition that needs age-specific structured care, not episodic follow-up.

Finally, two papers on the population scale. Endocrine Reviews carries an Endocrine Society scientific statement from Jastreboff, Ard, Hall and colleagues on obesity science in the era of nutrient-stimulated hormone-based medicines [9]. Explicitly not a treatment guideline, it maps what we still don't know: gaps in basic energy homeostasis, marked heterogeneity in who responds and how much, how to individualise targets beyond a weight number, the strengths and limits of real-world data, how best to combine lifestyle management with pharmacotherapy, and — importantly — long-term safety and the potential adverse consequences of weight loss itself. And in the Journal of Clinical Endocrinology and Metabolism, Kaegi-Braun and colleagues analysed nearly 940,000 Swedish singleton pregnancies and found gestational diabetes prevalence rose from about one and a half percent to over six and a half percent between 2015 and 2023, with the steepest rises among women who were foreign-born or had lower education or income [10]. The complication picture was nuanced: relative associations with obstetric complications were strongest in Swedish-born women and weaker among women born in Africa or the Eastern Mediterranean, yet absolute risks were not lower — women born in Africa and South-East Asia with gestational diabetes had higher absolute obstetric complication risk than Swedish-born women without it. Relative risk and absolute risk tell different stories, and equity planning needs the absolute one.

If you only have time for one paper this week, make it the United Kingdom fenofibrate study [1]. It is the paper most likely to change what you prescribe next week, and it raises a question you can act on immediately in a patient with background retinopathy and dyslipidaemia.

Here are the key takeaways from this week in Endocrinology. Fenofibrate was associated with meaningfully lower risk of sight-threatening retinopathy in type 2 diabetes compared with statins, though the benefit was not seen in South Asian patients. High-frequency spinal cord stimulation produced large pain reductions in painful diabetic neuropathy alongside blinded, objective improvements in sensory scores and nerve fibre density, suggesting more than symptom control. Sodium-glucose cotransporter inhibitors in type 1 diabetes remain unapproved for cardiac and kidney indications, and ketoacidosis risk mitigation is still evidence-poor. When a dexamethasone suppression test fails to suppress, consider measuring dexamethasone itself before diagnosing hypercortisolism. Expect axis recovery after adrenalectomy to take around eight months in mild autonomous cortisol secretion and well over a year in overt adrenal Cushing syndrome, and longer still in older patients. And rising gestational diabetes prevalence is concentrated in socially disadvantaged and migrant populations, where absolute complication risk is highest even when relative risk looks smaller.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.